$AADI
Aadi Bioscience, Inc. Stock $aadi

$aadi Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000162828023009583 Filed on March 29, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$5.867M	$5.227M	$15.22M
YoY Change	154.31%	-62.66%	1258.57%
Cost Of Revenue	$529.0K	$222.0K	$1.335M
YoY Change	195.53%
Gross Profit	$5.338M	$5.005M	$13.88M
YoY Change	150.85%		1139.38%
Gross Profit Margin	90.98%	95.75%	91.23%
Selling, General & Admin	$11.21M	$11.11M	$40.18M
YoY Change	22.51%	14.29%	117.04%
% of Gross Profit	209.95%	221.92%	289.43%
Research & Development	$10.96M	$9.370M	$32.66M
YoY Change	61.26%	29.65%	66.05%
% of Gross Profit	205.25%	187.21%	235.3%
Depreciation & Amortization	$38.00K	$46.00K	$159.0K
YoY Change	-48.65%	-36.11%	51.43%
% of Gross Profit	0.71%	0.92%	1.15%
Operating Expenses	$22.16M	$20.48M	$72.84M
YoY Change	39.02%	20.84%	-35.16%
Operating Profit	-$16.83M	-$15.47M	-$62.68M
YoY Change	21.8%		-43.64%
Interest Expense	$58.00K	$1.550M	$230.0K
YoY Change	0.0%	-3544.44%	-65.41%
% of Operating Profit
Other Income/Expense, Net	$1.602M		$2.168M
YoY Change	-3825.58%		92.03%
Pretax Income	-$15.22M	-$13.92M	-$60.51M
YoY Change	9.86%	-12.93%	-45.03%
Income Tax	$0.00	-$9.000K	$0.00
% Of Pretax Income
Net Earnings	-$15.20M	-$13.91M	-$60.50M
YoY Change	9.69%	-12.99%	-45.05%
Net Earnings / Revenue	-259.08%	-266.18%	-397.61%
Basic Earnings Per Share	-$0.57		-$2.69
Diluted Earnings Per Share	-$0.57	-$0.52	-$2.69
COMMON SHARES
Basic Shares Outstanding	24.44M shares	24.40M shares	22.51M shares
Diluted Shares Outstanding	26.86M shares		22.51M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$151.2M	$172.6M	$172.6M
YoY Change	16.42%	15.82%	15.82%
Cash & Equivalents	$34.05M	$39.02M	$39.02M
Short-Term Investments	$117.1M	$133.5M	$133.5M
Other Short-Term Assets	$4.388M	$3.746M	$3.746M
YoY Change	53.37%	64.08%	64.08%
Inventory	$3.803M	$1.861M	$1.861M
Prepaid Expenses
Receivables	$5.565M	$1.862M	$1.862M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$164.9M	$180.0M	$180.0M
YoY Change	21.61%	19.01%	19.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.225M	$508.0K	$2.030M
YoY Change	259.45%	791.23%	230.62%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change		-100.0%
Long-Term Investments
YoY Change
Other Assets	$2.062M	$2.178M	$2.178M
YoY Change	-11.77%	-1.58%	-1.58%
Total Long-Term Assets	$5.724M	$4.208M	$4.208M
YoY Change	-14.55%	-36.61%	-36.61%
TOTAL ASSETS
Total Short-Term Assets	$164.9M	$180.0M	$180.0M
Total Long-Term Assets	$5.724M	$4.208M	$4.208M
Total Assets	$170.7M	$184.2M	$184.2M
YoY Change	19.91%	16.67%	16.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.510M	$3.519M	$3.519M
YoY Change	62.34%	-45.35%	-45.35%
Accrued Expenses	$10.83M	$14.92M	$15.32M
YoY Change	47.65%	71.46%	78.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.75M	$18.84M	$18.84M
YoY Change	54.19%	23.32%	23.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$6.921M	$7.024M	$7.024M
YoY Change	11.97%		1381.86%
Total Long-Term Liabilities	$6.921M	$7.024M	$7.024M
YoY Change	11.97%		12.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.75M	$18.84M	$18.84M
Total Long-Term Liabilities	$6.921M	$7.024M	$7.024M
Total Liabilities	$24.67M	$25.86M	$25.86M
YoY Change	39.44%	20.25%	20.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$218.4M	-$203.2M
YoY Change	39.55%	42.41%
Common Stock	$364.4M	$361.7M
YoY Change	29.62%	29.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$146.0M	$158.4M	$158.4M
YoY Change
Total Liabilities & Shareholders Equity	$170.7M	$184.2M	$184.2M
YoY Change	19.91%	16.67%	16.67%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$15.20M	-$13.91M	-$60.50M
YoY Change	9.69%	-12.99%	-45.05%
Depreciation, Depletion And Amortization	$38.00K	$46.00K	$159.0K
YoY Change	-48.65%	-36.11%	51.43%
Cash From Operating Activities	-$21.31M	-$11.31M	-$49.64M
YoY Change	9.76%	-9.0%	121.38%
INVESTING ACTIVITIES
Capital Expenditures	$1.369M	$78.00K	$444.0K
YoY Change	5852.17%	-269.57%	865.22%
Acquisitions
YoY Change
Other Investing Activities	$17.70M	-$84.30M	-$132.4M
YoY Change			-625.58%
Cash From Investing Activities	$16.33M	-$84.38M	-$132.9M
YoY Change	-71095.65%	183332.61%	-628.31%
FINANCING ACTIVITIES
Cash Dividend Paid			$0.00
YoY Change			-100.0%
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$8.000K	-107.0K	$72.62M
YoY Change	-97.32%	-221.59%	-48.79%
NET CHANGE
Cash From Operating Activities	-$21.31M	-11.31M	-$49.64M
Cash From Investing Activities	$16.33M	-84.38M	-$132.9M
Cash From Financing Activities	$8.000K	-107.0K	$72.62M
Net Change In Cash	-$4.973M	-95.80M	-$109.9M
YoY Change	-74.02%	673.42%	-176.04%
FREE CASH FLOW
Cash From Operating Activities	-$21.31M	-$11.31M	-$49.64M
Capital Expenditures	$1.369M	$78.00K	$444.0K
Free Cash Flow	-$22.68M	-$11.39M	-$50.08M
YoY Change	16.67%	-8.03%	122.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001422142
CY2022	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2022#IntangibleAssetsNetExcludingGoodwill
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	us-gaap	Interest Expense InterestExpense	665000	usd
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	177896069	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24436990	shares
CY2022	dei	Auditor Firm AuditorFirmId	243
CY2022	dei	Auditor Name AuditorName	BDO USA, LLP
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39019000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	133541000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1862000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1861000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3746000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	180029000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1522000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3811000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2213000	usd
CY2021Q4	us-gaap	Assets Assets	157910000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6439000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8703000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	131000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18835000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1267000	usd
CY2022Q4	aadi	Due To Licensor DueToLicensor	5757000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	25859000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24435007	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24435007	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20894695	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	361689000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-115000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-203198000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	158378000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	184237000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15216000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1120000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40176000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18511000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32662000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19670000	usd
CY2022	aadi	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	0	usd
CY2021	aadi	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-1585000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	196000	usd
CY2022	us-gaap	Interest Expense InterestExpense	230000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2168000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1129000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60513000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-110088000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	647000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-60513000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-60513000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-110737000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-110737000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.69
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.69
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.41
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.41
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22511237	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22511237	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8923369	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8923369	shares
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	833000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-1000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2106000	usd
CY2021	aadi	Cumulative Dividends Paid On Series A Preferred Stock CumulativeDividendsPaidOnSeriesAPreferredStock	4412000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	136406000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	401000	usd
CY2022	aadi	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	55000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9643000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	323000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-115000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-60513000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	158378000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-60513000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110090000	usd
CY2022	aadi	Impairment Of Acquired Contract Intangible Asset ImpairmentOfAcquiredContractIntangibleAsset	3724000	usd
CY2021	aadi	Impairment Of Acquired Contract Intangible Asset ImpairmentOfAcquiredContractIntangibleAsset	74156000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	9643000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2106000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	-1215000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2022	aadi	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	0	usd
CY2021	aadi	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-1585000	usd
CY2022	aadi	Non Cash Interest Expense NonCashInterestExpense	0	usd
CY2021	aadi	Non Cash Interest Expense NonCashInterestExpense	665000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	196000	usd
CY2022	aadi	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	382000	usd
CY2021	aadi	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	171000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	159000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	105000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1862000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14149000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1861000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1463000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2166000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-437000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-481000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-291000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-129000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3220000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8290000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-8380000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49640000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	444000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	145192000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	12750000	usd
CY2022	aadi	Cash Acquired In Connection With Merger CashAcquiredInConnectionWithMerger	0	usd
CY2021	aadi	Cash Acquired In Connection With Merger CashAcquiredInConnectionWithMerger	29700000	usd
CY2022	aadi	Transaction Expenses Related To Merger TransactionExpensesRelatedToMerger	0	usd
CY2021	aadi	Transaction Expenses Related To Merger TransactionExpensesRelatedToMerger	4501000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-132886000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25153000	usd
CY2022	aadi	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	72500000	usd
CY2021	aadi	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	401000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	833000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	323000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	55000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	337000	usd
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	322000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9617000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	155000000	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	0	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	4412000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72620000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	141804000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-109906000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	144534000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148989000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4455000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39083000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148989000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	230000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	22000	usd
CY2022	aadi	Stock Issuance Costs StockIssuanceCosts	322000	usd
CY2021	aadi	Stock Issuance Costs StockIssuanceCosts	0	usd
CY2022	aadi	Issuance Of Common Stock Upon Merger IssuanceOfCommonStockUponMerger	0	usd
CY2021	aadi	Issuance Of Common Stock Upon Merger IssuanceOfCommonStockUponMerger	105888000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	9130000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	80000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1241000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	610000	usd
CY2021Q3	aadi	Anniversary Period Of Closing Of Merger Agreement AnniversaryPeriodOfClosingOfMergerAgreement	P20Y
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-203200000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-60500000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110100000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	172600000	usd
CY2021Q3	us-gaap	Shares Outstanding SharesOutstanding	8100000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2500000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	19000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	134000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	165576000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. In the opinion of management, all adjustments that are considered necessary for fair presentation have been included. The most significant estimates in the Company’s consolidated financial statements relate to fair value of the intangible asset, fair value of the convertible promissory notes, gross-to-net accruals, share-based compensation expense and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ion of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents, and investments in money market funds, United States government treasury bills, commercial paper, corporate bonds, and government agency debt securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. While the Company has not experienced any losses in such deposits, the recent failure of Silicon Valley Bank, at which the Company holds cash and cash equivalents in multiple accounts, exposed the Company to credit risk prior to the resolution by the Federal Deposit Insurance Corporation in a manner that fully protected all depositors. The Company has not experienced any losses on deposits since inception.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable is derived from customers located principally in the United States. The Company performs ongoing credit evaluations of its customers and maintains allowances for potential credit losses on customers’ accounts when deemed necessary. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</span></div>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39019000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148989000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	64000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39083000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148989000	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0	usd
CY2021Q4	aadi	Advanced Customer Payments Current AdvancedCustomerPaymentsCurrent	0	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1299000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	152000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	100000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	944000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	917000	usd
CY2022Q4	aadi	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	405000	usd
CY2021Q4	aadi	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	2287000	usd
CY2022Q4	aadi	Accrued Liabilities Other Sales Related Expenses Current AccruedLiabilitiesOtherSalesRelatedExpensesCurrent	1435000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	609000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	87000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	101000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	508000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57000	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P14Y3M18D
CY2021Q4	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	3900000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	0	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1465000	usd
CY2022Q4	aadi	Accrued Clinical Current AccruedClinicalCurrent	2399000	usd
CY2021Q4	aadi	Accrued Clinical Current AccruedClinicalCurrent	2507000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1814000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1948000	usd
CY2022Q4	aadi	Advanced Customer Payments Current AdvancedCustomerPaymentsCurrent	1571000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	698018	shares
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	100000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	74200000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	3900000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3700000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	165691000	usd
CY2021Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	74200000	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	3900000	usd
CY2022	aadi	Percentage Of Future Net Cash Proceeds Will Be Remitted To Contingent Value Rights Holders PercentageOfFutureNetCashProceedsWillBeRemittedToContingentValueRightsHolders	0.90
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P14Y3M18D
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3700000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	87000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	95000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3811000	usd
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	0	usd
CY2021	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	78062000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	87000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	95000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3724000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	74156000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3811000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5463000	usd
CY2021Q4	aadi	Accrued Liabilities Other Sales Related Expenses Current AccruedLiabilitiesOtherSalesRelatedExpensesCurrent	0	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	536000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	344000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14922000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8703000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1522000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	557000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	394000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	131000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1267000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	474000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1661000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	605000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	382000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	188000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	291000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	129000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	500000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	512000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	320000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	231000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	280000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	110000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1953000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	292000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	394000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P4Y6M10D
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.075
CY2022	aadi	Royalties On Net Product Sales RoyaltiesOnNetProductSales	1100000	usd
CY2022	aadi	Royalties Accrued On Product Sales RoyaltiesAccruedOnProductSales	400000	usd
CY2022	aadi	Right To Terminate License Agreement RightToTerminateLicenseAgreement	P120D
CY2022	aadi	Upfront Payment For License Agreement UpfrontPaymentForLicenseAgreement	14000000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14000000	usd
CY2021Q1	aadi	Upfront Payment For License Agreement UpfrontPaymentForLicenseAgreement	14000000	usd
CY2022	aadi	Amount Of Certain Development Regulatory And Sales Milestones Payments Eligible To Receive Under License Agreement AmountOfCertainDevelopmentRegulatoryAndSalesMilestonesPaymentsEligibleToReceiveUnderLicenseAgreement	257000000	usd
CY2019Q4	aadi	Proceeds From Issuance Of Convertible Notes ProceedsFromIssuanceOfConvertibleNotes	8100000	usd
CY2020Q1	aadi	Proceeds From Issuance Of Convertible Notes ProceedsFromIssuanceOfConvertibleNotes	1000000	usd
	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2019Q4	aadi	Convertible Notes Interest Rate For Fourth Month Date Of Loan Agreement ConvertibleNotesInterestRateForFourthMonthDateOfLoanAgreement	0.06
CY2020Q1	aadi	Convertible Notes Interest Rate For Fourth Month Date Of Loan Agreement ConvertibleNotesInterestRateForFourthMonthDateOfLoanAgreement	0.06
CY2019Q4	aadi	Convertible Notes Interest Rate For Fifth And Sixth Month Date Of Loan Agreement ConvertibleNotesInterestRateForFifthAndSixthMonthDateOfLoanAgreement	0.08
CY2020Q1	aadi	Convertible Notes Interest Rate For Fifth And Sixth Month Date Of Loan Agreement ConvertibleNotesInterestRateForFifthAndSixthMonthDateOfLoanAgreement	0.08
CY2019Q4	aadi	Convertible Notes Interest Rate For Remaining Sixth Months Term Until Maturity At Twelve Months ConvertibleNotesInterestRateForRemainingSixthMonthsTermUntilMaturityAtTwelveMonths	0.10
CY2020Q1	aadi	Convertible Notes Interest Rate For Remaining Sixth Months Term Until Maturity At Twelve Months ConvertibleNotesInterestRateForRemainingSixthMonthsTermUntilMaturityAtTwelveMonths	0.10
	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2020Q4	us-gaap	Debt Instrument Term DebtInstrumentTerm	P2Y
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.80
CY2021Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	698018	shares
CY2021Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	9500000	usd
CY2021	aadi	Gain Loss On Conversion Of Convertible Notes GainLossOnConversionOfConvertibleNotes	400000	usd
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24435007	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20894695	shares
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2558218	shares
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2022Q4	aadi	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1749876	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.71
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M23D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10007000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1583038	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.28
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	132084	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.04
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	210407	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	20.61
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2990423	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.28
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M2D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2849000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	722198	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.53
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y10M2D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2251000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2990423	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	19.28
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M2D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2849000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1300000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2106000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	300000	usd
CY2022Q2	aadi	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Outstanding Extended Exercise Ability Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndOutstandingExtendedExerciseAbilityNumberOfShares	64436	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	300000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.20
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.88
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	29167	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	36666	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	40000	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.29
CY2021	aadi	Number Of Class Of Warrants Exercised NumberOfClassOfWarrantsExercised	7500	shares
CY2022	aadi	Share Based Compensation Arrangement By Share Based Payment Award Stock Plan Offering Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod	P6M
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.004
CY2022	aadi	Effective Income Tax Rate Reconciliation Officer Compensation Percent EffectiveIncomeTaxRateReconciliationOfficerCompensationPercent	-0.017
CY2021	aadi	Effective Income Tax Rate Reconciliation Officer Compensation Percent EffectiveIncomeTaxRateReconciliationOfficerCompensationPercent	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.138
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.024
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.234
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.089
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	38548000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34228000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5168000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3732000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5417000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4219000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1214000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53352000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	39174000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52766000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38410000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	586000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	764000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	586000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	764000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	586000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	764000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14400000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28200000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2674000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2404000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	24000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	704000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	294000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3380000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2674000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	usd
CY2022	aadi	Net Operating Loss Cares Act Carryback Period NetOperatingLossCARESActCarrybackPeriod	P5Y
CY2022Q4	aadi	Accrued Clinical And Contract Manufacturing Expense AccruedClinicalAndContractManufacturingExpense	2800000	usd
CY2021Q4	aadi	Accrued Clinical And Contract Manufacturing Expense AccruedClinicalAndContractManufacturingExpense	4800000	usd
CY2022Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	1900000	usd
CY2022	aadi	Collaboration And Supply Agreement Expense CollaborationAndSupplyAgreementExpense	0	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001628280-23-009583-index-headers.html	Edgar Link	pending
0001628280-23-009583-index.html	Edgar Link	pending
0001628280-23-009583.txt	Edgar Link	pending
0001628280-23-009583-xbrl.zip	Edgar Link	pending
aadi-20221231.htm	Edgar Link	pending
aadi-20221231.xsd	Edgar Link	pending
aadi-20221231xex1017amende.htm	Edgar Link	pending
aadi-20221231xex1021xnegot.htm	Edgar Link	pending
aadi-20221231xex104xamende.htm	Edgar Link	pending
aadi-20221231xex211xsubsid.htm	Edgar Link	pending
aadi-20221231xex231xaudito.htm	Edgar Link	pending
aadi-20221231xex31.htm	Edgar Link	pending
aadi-20221231xex32.htm	Edgar Link	pending
aadi-20221231xex41xdescrip.htm	Edgar Link	pending
aadi-20221231_g1.jpg	Edgar Link	pending
aadi-20221231_g10.jpg	Edgar Link	pending
aadi-20221231_g11.jpg	Edgar Link	pending
aadi-20221231_g12.jpg	Edgar Link	pending
aadi-20221231_g2.jpg	Edgar Link	pending
aadi-20221231_g3.jpg	Edgar Link	pending
aadi-20221231_g4.jpg	Edgar Link	pending
aadi-20221231_g5.jpg	Edgar Link	pending
aadi-20221231_g6.jpg	Edgar Link	pending
aadi-20221231_cal.xml	Edgar Link	unprocessable
aadi-20221231_def.xml	Edgar Link	unprocessable
aadi-20221231_g7.jpg	Edgar Link	pending
aadi-20221231_g8.jpg	Edgar Link	pending
aadi-20221231_g9.jpg	Edgar Link	pending
bresunsetcoastllc-office.htm	Edgar Link	pending
bresunsetcoastllc-office001.jpg	Edgar Link	pending
bresunsetcoastllc-office002.jpg	Edgar Link	pending
bresunsetcoastllc-office003.jpg	Edgar Link	pending
bresunsetcoastllc-office004.jpg	Edgar Link	pending
bresunsetcoastllc-office005.jpg	Edgar Link	pending
bresunsetcoastllc-office006.jpg	Edgar Link	pending
bresunsetcoastllc-office007.jpg	Edgar Link	pending
bresunsetcoastllc-office008.jpg	Edgar Link	pending
bresunsetcoastllc-office009.jpg	Edgar Link	pending
bresunsetcoastllc-office010.jpg	Edgar Link	pending
bresunsetcoastllc-office011.jpg	Edgar Link	pending
bresunsetcoastllc-office012.jpg	Edgar Link	pending
bresunsetcoastllc-office013.jpg	Edgar Link	pending
bresunsetcoastllc-office014.jpg	Edgar Link	pending
bresunsetcoastllc-office015.jpg	Edgar Link	pending
bresunsetcoastllc-office016.jpg	Edgar Link	pending
bresunsetcoastllc-office017.jpg	Edgar Link	pending
bresunsetcoastllc-office018.jpg	Edgar Link	pending
bresunsetcoastllc-office019.jpg	Edgar Link	pending
bresunsetcoastllc-office020.jpg	Edgar Link	pending
bresunsetcoastllc-office021.jpg	Edgar Link	pending
bresunsetcoastllc-office022.jpg	Edgar Link	pending
bresunsetcoastllc-office023.jpg	Edgar Link	pending
bresunsetcoastllc-office024.jpg	Edgar Link	pending
bresunsetcoastllc-office025.jpg	Edgar Link	pending
bresunsetcoastllc-office026.jpg	Edgar Link	pending
bresunsetcoastllc-office027.jpg	Edgar Link	pending
bresunsetcoastllc-office028.jpg	Edgar Link	pending
bresunsetcoastllc-office029.jpg	Edgar Link	pending
bresunsetcoastllc-office030.jpg	Edgar Link	pending
bresunsetcoastllc-office031.jpg	Edgar Link	pending
bresunsetcoastllc-office032.jpg	Edgar Link	pending
bresunsetcoastllc-office033.jpg	Edgar Link	pending
bresunsetcoastllc-office034.jpg	Edgar Link	pending
bresunsetcoastllc-office035.jpg	Edgar Link	pending
bresunsetcoastllc-office036.jpg	Edgar Link	pending
bresunsetcoastllc-office037.jpg	Edgar Link	pending
bresunsetcoastllc-office038.jpg	Edgar Link	pending
bresunsetcoastllc-office039.jpg	Edgar Link	pending
bresunsetcoastllc-office040.jpg	Edgar Link	pending
aadi-20221231_htm.xml	Edgar Link	completed
bresunsetcoastllc-office041.jpg	Edgar Link	pending
bresunsetcoastllc-office042.jpg	Edgar Link	pending
bresunsetcoastllc-office043.jpg	Edgar Link	pending
bresunsetcoastllc-office044.jpg	Edgar Link	pending
bresunsetcoastllc-office045.jpg	Edgar Link	pending
bresunsetcoastllc-office046.jpg	Edgar Link	pending
bresunsetcoastllc-office047.jpg	Edgar Link	pending
bresunsetcoastllc-office048.jpg	Edgar Link	pending
bresunsetcoastllc-office049.jpg	Edgar Link	pending
bresunsetcoastllc-office050.jpg	Edgar Link	pending
bresunsetcoastllc-office051.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aadi-20221231_pre.xml	Edgar Link	unprocessable
aadi-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AADI
Aadi Bioscience, Inc. Stock $aadi

2023 Q1 Form 10-K Financial Statement

#000162828023009583 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AADI Aadi Bioscience, Inc. Stock $aadi

2023 Q1 Form 10-K Financial Statement

#000162828023009583 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AADI
Aadi Bioscience, Inc. Stock $aadi